JP2002506204A - 可逆的アフィニティー電気泳動を用いる精製および検出プロセス - Google Patents

可逆的アフィニティー電気泳動を用いる精製および検出プロセス

Info

Publication number: JP2002506204A
Authority: JP; Japan
Prior art keywords: analyte; electrophoretic medium; electric field; affinity ligand; changed
Prior art date: 1998-03-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2000534862A

Other languages

English (en)

Japanese (ja)

Inventor

アブラムス，エズラ，エス．

ハモンド，フィリップ，ダブリュ．

ミュア，アンドリュー，アール．

ボールズ，ティー．，クリスチャン

Original Assignee

モザイクテクノロジーズ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-03

Filing date

1999-03-03

Publication date

2002-02-26

1999-03-03 Application filed by モザイクテクノロジーズ filed Critical モザイクテクノロジーズ

2002-02-26 Publication of JP2002506204A publication Critical patent/JP2002506204A/ja

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 87
230000002441 reversible effect Effects 0.000 title claims abstract description 11
238000000746 purification Methods 0.000 title abstract description 34
230000008569 process Effects 0.000 title abstract description 16
238000001514 detection method Methods 0.000 title abstract description 12
238000002299 affinity electrophoresis Methods 0.000 title abstract description 6
239000003446 ligand Substances 0.000 claims abstract description 135
239000012491 analyte Substances 0.000 claims abstract description 126
238000009739 binding Methods 0.000 claims abstract description 49
230000027455 binding Effects 0.000 claims abstract description 48
238000001962 electrophoresis Methods 0.000 claims abstract description 37
239000000463 material Substances 0.000 claims abstract description 6
150000007523 nucleic acids Chemical class 0.000 claims description 78
102000039446 nucleic acids Human genes 0.000 claims description 69
108020004707 nucleic acids Proteins 0.000 claims description 69
230000005684 electric field Effects 0.000 claims description 42
230000000295 complement effect Effects 0.000 claims description 26
230000008859 change Effects 0.000 claims description 24
229920000642 polymer Polymers 0.000 claims description 24
108090000623 proteins and genes Proteins 0.000 claims description 22
102000004169 proteins and genes Human genes 0.000 claims description 19
239000000872 buffer Substances 0.000 claims description 18
238000009396 hybridization Methods 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 17
239000002773 nucleotide Substances 0.000 claims description 17
125000003729 nucleotide group Chemical group 0.000 claims description 17
102000004190 Enzymes Human genes 0.000 claims description 14
108090000790 Enzymes Proteins 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 13
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical group NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 12
238000012360 testing method Methods 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 9
108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
239000000758 substrate Substances 0.000 claims description 7
239000004202 carbamide Substances 0.000 claims description 5
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 5
108091023037 Aptamer Proteins 0.000 claims description 4
108010066717 Q beta Replicase Proteins 0.000 claims description 4
150000001720 carbohydrates Chemical class 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
238000001816 cooling Methods 0.000 claims description 3
238000010438 heat treatment Methods 0.000 claims description 3
230000001105 regulatory effect Effects 0.000 claims description 3
230000005679 Peltier effect Effects 0.000 claims description 2
150000001413 amino acids Chemical class 0.000 claims description 2
239000002738 chelating agent Substances 0.000 claims description 2
239000005515 coenzyme Substances 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
229940088598 enzyme Drugs 0.000 claims description 2
239000002532 enzyme inhibitor Substances 0.000 claims description 2
239000007850 fluorescent dye Substances 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
-1 inorganic molecules Substances 0.000 claims description 2
150000002632 lipids Chemical class 0.000 claims description 2
150000002772 monosaccharides Chemical class 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
238000013508 migration Methods 0.000 claims 1
230000005012 migration Effects 0.000 claims 1
239000002777 nucleoside Substances 0.000 claims 1
150000003833 nucleoside derivatives Chemical class 0.000 claims 1
238000000926 separation method Methods 0.000 abstract description 29
230000000737 periodic effect Effects 0.000 abstract description 4
239000000499 gel Substances 0.000 description 59
239000000523 sample Substances 0.000 description 54
108091032973 (ribonucleotides)n+m Proteins 0.000 description 45
239000000306 component Substances 0.000 description 25
241000588724 Escherichia coli Species 0.000 description 19
238000010494 dissociation reaction Methods 0.000 description 16
230000005593 dissociations Effects 0.000 description 15
230000037230 mobility Effects 0.000 description 11
239000000047 product Substances 0.000 description 11
108020004414 DNA Proteins 0.000 description 9
229920002401 polyacrylamide Polymers 0.000 description 8
238000002360 preparation method Methods 0.000 description 7
238000011160 research Methods 0.000 description 7
230000009870 specific binding Effects 0.000 description 7
229920000936 Agarose Polymers 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000012937 correction Methods 0.000 description 6
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
238000005251 capillar electrophoresis Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
108020004465 16S ribosomal RNA Proteins 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000013578 denaturing buffer Substances 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
239000000178 monomer Substances 0.000 description 4
108020004418 ribosomal RNA Proteins 0.000 description 4
238000007873 sieving Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
239000002131 composite material Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000003252 repetitive effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
VHTUHGNVVZPWGO-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethyl-8-(pyridin-3-ylmethyl)purine-2,6-dione Chemical compound OCCN1C=2C(=O)N(C)C(=O)N(C)C=2N=C1CC1=CC=CN=C1 VHTUHGNVVZPWGO-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
101710137500 T7 RNA polymerase Proteins 0.000 description 2
239000012163 TRI reagent Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000001261 affinity purification Methods 0.000 description 2
230000003321 amplification Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
125000003636 chemical group Chemical group 0.000 description 2
239000002826 coolant Substances 0.000 description 2
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000007429 general method Methods 0.000 description 2
239000011544 gradient gel Substances 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
239000002523 lectin Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
150000003141 primary amines Chemical group 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000012552 review Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
KYZUDXYWLHVWCQ-UHFFFAOYSA-N 2-ethenyl-7h-purin-6-amine Chemical group NC1=NC(C=C)=NC2=C1NC=N2 KYZUDXYWLHVWCQ-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000272194 Ciconiiformes Species 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
241000944748 Quesada Species 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
102000004167 Ribonuclease P Human genes 0.000 description 1
108090000621 Ribonuclease P Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
239000008051 TBE buffer Substances 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
150000003926 acrylamides Chemical class 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000008901 benefit Effects 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
230000014670 detection of bacterium Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
238000007834 ligase chain reaction Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012533 medium component Substances 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
108091008104 nucleic acid aptamers Proteins 0.000 description 1
102000044158 nucleic acid binding protein Human genes 0.000 description 1
108700020942 nucleic acid binding protein Proteins 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920002939 poly(N,N-dimethylacrylamides) Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000007693 zone electrophoresis Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
- G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
- G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44773—Multi-stage electrophoresis, e.g. two-dimensional electrophoresis

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Electrochemistry (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Immunology (AREA)
Pathology (AREA)
Spectroscopy & Molecular Physics (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

JP2000534862A 1998-03-03 1999-03-03 可逆的アフィニティー電気泳動を用いる精製および検出プロセス Pending JP2002506204A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7661498P	1998-03-03	1998-03-03
US60/076,614		1998-03-03
PCT/US1999/004849 WO1999045374A2 (fr)	1998-03-03	1999-03-03	Procedes de purification et de detection par electrophorese d'affinite reversible

Publications (1)

Publication Number	Publication Date
JP2002506204A true JP2002506204A (ja)	2002-02-26

Family

ID=22133151

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000534862A Pending JP2002506204A (ja)	1998-03-03	1999-03-03	可逆的アフィニティー電気泳動を用いる精製および検出プロセス

Country Status (5)

Country	Link
EP (1)	EP1068518A2 (fr)
JP (1)	JP2002506204A (fr)
AU (1)	AU2896399A (fr)
CA (1)	CA2322975A1 (fr)
WO (1)	WO1999045374A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002350400A (ja) *	2001-05-29	2002-12-04	Aloka Co Ltd	電気泳動装置
JP2007512509A (ja) *	2003-11-05	2007-05-17	エグザクトサイエンシーズコーポレイション	反復的親和性分離およびその使用
JP2009516176A (ja) *	2005-11-10	2009-04-16	テラダイン、インコーポレイテッド	ローカルに順序付けられたストロービング
JP2010508496A (ja) *	2006-08-29	2010-03-18	ベクトン・ディキンソン・アンド・カンパニー	無担体の偏向電気泳動の方法及び装置
JP2010536790A (ja) *	2007-08-17	2010-12-02	パーデュー・リサーチ・ファウンデーション	Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US9636413B2 (en)	2012-11-15	2017-05-02	Endocyte, Inc.	Conjugates for treating diseases caused by PSMA expressing cells
US9951324B2 (en)	2010-02-25	2018-04-24	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10188759B2 (en)	2015-01-07	2019-01-29	Endocyte, Inc.	Conjugates for imaging
US10398791B2 (en)	2013-10-18	2019-09-03	Deutsches Krebsforschungszentrum	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US12178892B2 (en)	2013-11-14	2024-12-31	Purdue Research Foundation	Compounds for positron emission tomography
US12208102B2 (en)	2018-04-17	2025-01-28	Endocyte, Inc.	Methods of treating cancer

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU730491B2 (en)	1997-05-16	2001-03-08	Exact Sciences Corporation	Electrophoretic analysis of molecules using immobilized probes
DE60029092T2 (de)	1999-04-09	2007-02-01	Exact Sciences Corp., Marlborough	Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
US6586177B1 (en)	1999-09-08	2003-07-01	Exact Sciences Corporation	Methods for disease detection
US6849403B1 (en)	1999-09-08	2005-02-01	Exact Sciences Corporation	Apparatus and method for drug screening
FR2799988B1 (fr)	1999-10-26	2001-12-07	Centre Nat Rech Scient	Procede de separation d'un compose chimique ou biologique dans un melange de composes similaires par diffusion dans un milieu tel qu'un gel
US6919174B1 (en)	1999-12-07	2005-07-19	Exact Sciences Corporation	Methods for disease detection
AU4714201A (en)	1999-12-07	2001-06-18	Exact Sciences Corporation	Supracolonic aerodigestive neoplasm detection
FR2806161B1 (fr) *	2000-03-10	2002-09-20	Sebia Sa	Methode de separation, d'identification et de quantification des isophosphatases alcalines par electrophorese
US10337054B2 (en)	2004-02-02	2019-07-02	Quantum-Si Incorporated	Enrichment of nucleic acid targets
US8529744B2 (en)	2004-02-02	2013-09-10	Boreal Genomics Corp.	Enrichment of nucleic acid targets
US9186685B2 (en)	2012-01-13	2015-11-17	The University Of British Columbia	Multiple arm apparatus and methods for separation of particles
WO2005072854A1 (fr)	2004-02-02	2005-08-11	The University Of British Columbia	Scodaphorese, procedes et appareil utilises pour deplacer et concentrer des particules
WO2009094772A1 (fr)	2008-02-01	2009-08-06	The University Of British Columbia	Procédés et appareil pour l'introduction et la récupération de particules
WO2010121381A1 (fr)	2009-04-21	2010-10-28	The University Of British Columbia	Système et procédés pour la détection de particules
CA2742327A1 (fr)	2011-05-20	2012-11-20	The University Of British Columiba	Systemes et methodes pour amelioration de la scoda (separation, concentration, detection de molecules selon la difference d'affinite de liaison)
WO2013166444A2 (fr)	2012-05-04	2013-11-07	Boreal Genomics Corp.	Analyse de biomarqueurs utilisant la scodaphorèse
US9340835B2 (en)	2013-03-15	2016-05-17	Boreal Genomics Corp.	Method for separating homoduplexed and heteroduplexed nucleic acids
US11130986B2 (en)	2015-05-20	2021-09-28	Quantum-Si Incorporated	Method for isolating target nucleic acid using heteroduplex binding proteins
AU2020372908A1 (en)	2019-10-29	2022-06-02	Quantum-Si Incorporated	Peristaltic pumping of fluids and associated methods, systems, and devices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5167790A (en) *	1985-09-27	1992-12-01	Washington University	Field-inversion gel electrophoresis
GB9502660D0 (en) *	1995-02-10	1995-03-29	Univ London	Detection of mutations or variations in DNA
US6379515B1 (en) *	1996-05-24	2002-04-30	Novartis Ag	Process for separating mixtures of substances using capillary affinity gel electrophoresis

1999
- 1999-03-03 EP EP99909853A patent/EP1068518A2/fr not_active Withdrawn
- 1999-03-03 AU AU28963/99A patent/AU2896399A/en not_active Abandoned
- 1999-03-03 CA CA002322975A patent/CA2322975A1/fr not_active Abandoned
- 1999-03-03 WO PCT/US1999/004849 patent/WO1999045374A2/fr not_active Application Discontinuation
- 1999-03-03 JP JP2000534862A patent/JP2002506204A/ja active Pending

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002350400A (ja) *	2001-05-29	2002-12-04	Aloka Co Ltd	電気泳動装置
JP2007512509A (ja) *	2003-11-05	2007-05-17	エグザクトサイエンシーズコーポレイション	反復的親和性分離およびその使用
JP2009516176A (ja) *	2005-11-10	2009-04-16	テラダイン、インコーポレイテッド	ローカルに順序付けられたストロービング
US8795494B2 (en)	2006-08-29	2014-08-05	Becton, Dickinson And Company	Methods and apparatus for carrier-free deflection electrophoresis
JP2010508496A (ja) *	2006-08-29	2010-03-18	ベクトン・ディキンソン・アンド・カンパニー	無担体の偏向電気泳動の方法及び装置
US10046054B2 (en)	2007-08-17	2018-08-14	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US11083710B2 (en)	2007-08-17	2021-08-10	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US11717514B2 (en)	2007-08-17	2023-08-08	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US11369590B2 (en)	2007-08-17	2022-06-28	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
JP2010536790A (ja) *	2007-08-17	2010-12-02	パーデュー・リサーチ・ファウンデーション	Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US10646581B2 (en)	2007-08-17	2020-05-12	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US11318121B2 (en)	2007-08-17	2022-05-03	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US11298341B2 (en)	2007-08-17	2022-04-12	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10406240B2 (en)	2007-08-17	2019-09-10	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US8907058B2 (en)	2007-08-17	2014-12-09	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10485878B2 (en)	2007-08-17	2019-11-26	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10517957B2 (en)	2007-08-17	2019-12-31	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10517956B2 (en)	2007-08-17	2019-12-31	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10828282B2 (en)	2007-08-17	2020-11-10	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10624970B2 (en)	2007-08-17	2020-04-21	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10624971B2 (en)	2007-08-17	2020-04-21	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10624969B2 (en)	2007-08-17	2020-04-21	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US9951324B2 (en)	2010-02-25	2018-04-24	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US12091693B2 (en)	2010-02-25	2024-09-17	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US10557128B2 (en)	2010-02-25	2020-02-11	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US11155800B2 (en)	2010-02-25	2021-10-26	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
US9782493B2 (en)	2012-11-15	2017-10-10	Endocyte, Inc.	Conjugates for treating diseases caused by PSMA expressing cells
US10912840B2 (en)	2012-11-15	2021-02-09	Endocyte, Inc.	Conjugates for treating diseases caused by PSMA expressing cells
US9636413B2 (en)	2012-11-15	2017-05-02	Endocyte, Inc.	Conjugates for treating diseases caused by PSMA expressing cells
US11045564B2 (en)	2013-10-18	2021-06-29	Deutsches Krebsforschungszentrum	Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
US10398791B2 (en)	2013-10-18	2019-09-03	Deutsches Krebsforschungszentrum	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10471160B2 (en)	2013-10-18	2019-11-12	Deutsches Krebsforschungszentrum	Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US11931430B2 (en)	2013-10-18	2024-03-19	Novartis Ag	Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
US11951190B2 (en)	2013-10-18	2024-04-09	Novartis Ag	Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
US12178892B2 (en)	2013-11-14	2024-12-31	Purdue Research Foundation	Compounds for positron emission tomography
US10188759B2 (en)	2015-01-07	2019-01-29	Endocyte, Inc.	Conjugates for imaging
US10898596B2 (en)	2015-01-07	2021-01-26	Endocyte, Inc.	Conjugates for imaging
US12208102B2 (en)	2018-04-17	2025-01-28	Endocyte, Inc.	Methods of treating cancer

Also Published As

Publication number	Publication date
WO1999045374A3 (fr)	2000-02-17
WO1999045374A2 (fr)	1999-09-10
EP1068518A2 (fr)	2001-01-17
AU2896399A (en)	1999-09-20
CA2322975A1 (fr)	1999-09-10

Publication	Publication Date	Title
JP2002506204A (ja)	2002-02-26	可逆的アフィニティー電気泳動を用いる精製および検出プロセス
US7452668B2 (en)	2008-11-18	Electrophoretic analysis of molecules using immobilized probes
US6238927B1 (en)	2001-05-29	Reverse displacement assay for detection of nucleic acid sequences
US4302204A (en)	1981-11-24	Transfer and detection of nucleic acids
US5824478A (en)	1998-10-20	Diagnostic methods and probes
Davison et al.	1979	Purification of Bacillus subtilis RNA polymerase with heparin-agarose. In vitro transcription of phi 29 DNA.
US20020197614A1 (en)	2002-12-26	Electrophoretic analysis of target molecules using adapter molecules
US5747254A (en)	1998-05-05	Promotion of high specificity molecular assembly
AU760236B2 (en)	2003-05-08	Denaturing gradient affinity electrophoresis and methods of use thereof
Brimacombe et al.	1988	[19] Intra-RNA and RNA—protein cross-linking techniques in Escherichia coli ribosomes
US7767468B2 (en)	2010-08-03	Repetitive affinity separation and uses therefor
Woodson et al.	2009	Analysis of RNA folding by native polyacrylamide gel electrophoresis
US20090325153A1 (en)	2009-12-31	Analysis of heterogeneous nucleic acid samples
AU4053900A (en)	2000-10-23	Electrophoretic analysis of target molecules using adapter molecules
JP4940456B2 (ja)	2012-05-30	標的に対して高い親和性で結合する核酸を選択する方法
Singhal et al.	2000	DNA annealing and DNA–protein interactions by capillary electrophoresis
US20130048487A1 (en)	2013-02-28	Systems and methods for enrichment and detection of particles
WO2013026161A1 (fr)	2013-02-28	Systèmes et procédés pour l'enrichissement et la détection de particules
JP4019433B2 (ja)	2007-12-12	核酸結合用粒子担体
JP2003532073A5 (fr)	2008-06-19
Expert-Bezançon et al.	1988	[20] RNA—protein cross-linking
JP2006166785A (ja)	2006-06-29	相互作用測定方法
CA2750428A1 (fr)	2013-02-25	Systemes et methodes pour l'enrichissement et la detection de particules

Legal Events

Date	Code	Title	Description
2006-03-04	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060303
2009-03-16	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090313
2009-09-04	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090903

Date

Code

Title

Description

2006-03-04

A621

Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060303

2009-03-16

A131

Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090313

2009-09-04

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090903